The Gastrointestinal and Other Cancers Research Group conducts and supports prevention and early detection research on colorectal, esophageal, liver, pancreatic, and hematolymphoid cancers, as well as new approaches to clinical prevention studies including cancer immunoprevention.
Barrett’s Esophagus Translational Research Network (BETRNet)
The Barrett’s Esophagus Translational Research Network (BETRNet) is directed from this group in partnership with NCI’s Division of Cancer Biology. The goal of BETRNet is to reduce the incidence, morbidity, and mortality of esophageal adenocarcinoma by answering key questions related to the progression of the disease, especially in the premalignant stage. Multidisciplinary translational research centers collaborate to better understand the biology of Barrett's esophagus and esophageal adenocarcinoma to improve risk stratification and develop prevention strategies.
Phase 0/I/II Cancer Prevention Clinical Trials Program
This group jointly administers the Phase 0/I/II Cancer Prevention Clinical Trials Program evaluating new agents, surrogate biomarkers, and technologies to identify premalignant lesions, and related cancers.
PREVENT Cancer Preclinical Drug Development Program
The group works closely with the PREVENT Program, housed in the Chemopreventive Agent Development Research Group, on developing new animal models for cancer that can be used to evaluate chemopreventive agents as well as developing new agents.